2640981-19-5
Chemical Structure
Polzastobart
Synonym(s): JTX-8064
- CAS No.: 2640981-19-5
- Formula:N/A
- Molecular Weight:(146.48 kDa)
SMILES: [Polzastobart]
Biological Activity:
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody and LILRB2 (ILT4) antagonist. Polzastobart specifically binds to and antagonizes LILRB2, relieves ILT4-mediated myeloid immunosuppression, and promotes the polarization of macrophages from an M2-like phenotype to an M1-like phenotype. Polzastobart induces macrophage polarization, IFNγ signaling, and T cell inflammation-related pharmacodynamic responses in ex vivo human renal cancer, lung cancer, and head and neck cancer tissues. Polzastobart can be used in studies related to tumor-associated macrophages and tumor immunity. For the isotype control of Polzastobart, refer to: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Polzastobart | 97.81% | Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody and LILRB2 (ILT4) antagonist. Polzastobart specifically binds to and antagonizes LILRB2, relieves ILT4-mediated myeloid immunosuppression, and promotes the polarization of macrophages from an M2-like phenotype to an M1-like phenotype. Polzastobart induces macrophage polarization, IFNγ signaling, and T cell inflammation-related pharmacodynamic responses in ex vivo human renal cancer, lung cancer, and head and neck cancer tissues. Polzastobart can be used in studies related to tumor-associated macrophages and tumor immunity. For the isotype control of Polzastobart, refer to: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003). |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. World Health Organization. Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. World Health Organization. 2024.
- [2]. Hashambhoy-Ramsay Y, et al. Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development. Journal for ImmunoTherapy of Cancer. 2020;8(Suppl 3):A129-A130.
- [3]. Beers C, et al. Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway. Journal for immunotherapy of cancer. 2026 Feb 15;14(2):e013313. [Content Brief]
